REDWOOD CITY, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- myoscience, inc. is pleased to announce the appointment of Jeffrey Gold as Chief Executive Officer (CEO) effective immediately. Mr. Gold, who previously held the position of President & COO, is an accomplished executive, having held posts as Chief Executive for Velomedix and CryoVascular Systems as well as Chief Operating Officer for CardioThoracic Systems.
"I am very pleased to handover the role of Chief Executive Officer to Jeff Gold. Jeff is a seasoned executive with a solid record of success. The myoscience Board of Directors fully supports the appointment and we are excited to have Jeff accept the leadership role as CEO," said Rich Ferrari, myoscience Executive Chairman.
Prior to joining myoscience, Mr. Gold was the President & CEO of Velomedix Inc, a venture backed company that developed a unique technology for rapidly inducing therapeutic hypothermia in patients undergoing severe acute cardiovascular events, such as heart attack and cardiac arrest. Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices.
"I am very excited to assume the responsibility of guiding myoscience through its next development stage," said Gold. "The myoscience team has built an extremely strong platform technology that targets two distinct markets, aesthetics (for facial wrinkles) and peripheral nerve pain, both with tremendous potential. The patented iovera° product platform has demonstrated the ability to improve patients' lives in the aesthetics and pain management applications that is unmatched in those fields. We have a strong team of dedicated professionals that will drive myoscience to greater success in the future."
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the iovera° system. The iovera° system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=25085
© 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0327 REV A
CONTACT: MEDIA RELATIONS Peter Osborne / email@example.com